Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Marlise R. Luskin(Dana-Farber Cancer Institute), Ran Reshef(Abramson Cancer Center), Jennifer J.D. Morrissette(University of Pennsylvania), Martin Carroll(University of Pennsylvania), Lisa Crisalli(University of Pennsylvania), David Porter(University of Pennsylvania), David B Roth(University of Pennsylvania), Jianhua Zhao(University of Pennsylvania), David Lieberman(University of Pennsylvania), Selina M. Luger(University of Pennsylvania)
Biology of Blood and Marrow Transplantation
July 29, 2016
10.1016/j.bbmt.2016.07.018
Cited by 38

Related Papers

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Anthracycline Dose Intensification in Acute Myeloid Leukemia
|New England Journal of Medicine|2009|907
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
|Blood|2006|843
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)
|Blood|2007|782